http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
-
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
-
GBS Inc. to Participate in the Upcoming March Investor Conferences
-
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
-
GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test
-
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
-
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
-
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
-
GBS Inc. (GBS) appoints Professor Steven Boyages, PhD, Chairman, to position of Interim Chief Executive Officer
-
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
-
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
-
GBS Inc. (GBS) Files Pre-Submission with the FDA
-
GBS Inc. Announces its Pre-Submission package is with the FDA
-
GBS Inc. Announces its Pre-Submission package is with the FDA
-
GBS Inc. to Present at Upcoming September Virtual Investor Conferences
-
GBS Inc. to Present at Upcoming September Virtual Investor Conferences
-
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
-
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
-
GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11
-
GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11
-
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
-
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
-
GBS Inc. (GBS) Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
-
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
-
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
-
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
-
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey

